Compare ESCA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | AVXL |
|---|---|---|
| Founded | 1922 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.8M | 251.1M |
| IPO Year | 1995 | 2013 |
| Metric | ESCA | AVXL |
|---|---|---|
| Price | $18.84 | $2.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 38.1K | ★ 879.2K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 6.45 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $180,541,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $58.50 | ★ N/A |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $11.41 | $2.61 |
| 52 Week High | $21.32 | $13.99 |
| Indicator | ESCA | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 32.27 |
| Support Level | $17.25 | $2.61 |
| Resistance Level | $18.72 | $3.50 |
| Average True Range (ATR) | 0.91 | 0.18 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 28.57 | 6.39 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.